The effects of disease-modifying therapies in SMA-5q type 1 and the importance of early diagnosis of the disease
- Weitere Titel
-
Os efeitos das terapias modificadoras da doença na atrofia muscular espinhal 5q do tipo 1 e a importância do diagnóstico precoce da doença
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
The effects of disease-modifying therapies in SMA-5q type 1 and the importance of early diagnosis of the disease ; volume:82 ; number:11 ; year:2024 ; pages:001-002
Arquivos de neuro-psiquiatria ; 82, Heft 11 (2024), 001-002
- Beteiligte Personen und Organisationen
-
Zanoteli, Edmar
- DOI
-
10.1055/s-0044-1800927
- URN
-
urn:nbn:de:101:1-2502061052195.109127869321
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zanoteli, Edmar
Ähnliche Objekte (12)
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Outcome of MS relapses in the era of disease-modifying therapy
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Amisulpride as a potential disease-modifying drug in the treatment of tauopathies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Outcome of MS relapses in the era of disease-modifying therapy
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Amisulpride as a potential disease-modifying drug in the treatment of tauopathies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Outcome of MS relapses in the era of disease-modifying therapy
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Amisulpride as a potential disease-modifying drug in the treatment of tauopathies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin